Recruiting OBSERVATIONAL NCT06321640

Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies. (POSITive)

POSITive: Prospective Observational Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies

Sponsor: European Institute of Oncology

Conditions Breast Cancer Colorectal Cancer Head and Neck Cancer Liver Metastases Lung Cancer Lung Metastases Melanoma Urothelial Carcinoma

Interventions Cohort A: primarily operable disease, candidate to adjuvant Cohort B: locally advanced disease Cohort C: metastatic disease Cohort D: Progressive disease Cohort E: Hematological neoplasms Cohort F: Toxicity

Updated 3 times since 2024 Last updated: Mar 13, 2024 Started: Jul 8, 2022 Primary completion: Dec 31, 2024 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Breast Cancer and Colorectal Cancer, this trial is actively recruiting participants. The trial is conducted by European Institute of Oncology and has accumulated 3 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting
Jul 2024 — Sep 2024 [monthly]

Recruiting
Apr 2024 — Jul 2024 [monthly]

Recruiting

First recorded

Jul 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Institute of Oncology

Data source: European Institute of Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milan, Italy